Abstract

Glioma stem cells (GSCs) have been considered to be responsible for treatment failure due to their self-renewal and limitless proliferative property. Recently, the Na+/K+-ATPase a1 (ATP1A1) subunit was described as a novel therapeutic target for gliomas. Interestingly, our previous proteomics study revealed that ATP1A1 is remarkably overexpressed in GSCs. In the current study, we investigated the role of ATP1A1 in regulating growth, survival, and tumorigenicity of primary human GSCs and the underlying molecular mechanism. We tested RNA and protein expression of ATP1A1 in glioma tissues and GSCs. In addition, we knocked down ATP1A1 in GSCs and assessed the effects thereof on growth, survival, and apoptosis. The role of ATP1A1 in signaling pathways was investigated in vitro. We found that the ATP1A1 expression level was associated with the grade of glioma. Knockdown of ATP1A1 in GSCs in vitro inhibited cell proliferation and survival, increased apoptosis, and halted cell-cycle progression at the G1 phase. Cell proliferation and survival were resumed upon rescue of ATP1A1 expression in ATP1A1-knockdown GSCs. The ERK1/2 and AKT pathways were inhibited through suppression of Src phosphorylation by ATP1A1 knockdown. Collectively, our findings suggest that ATP1A1 overexpression promotes GSC growth and proliferation by affecting Src phosphorylation to activate the ERK1/2 and AKT signaling pathways.

Highlights

  • Glioblastoma (GBM) is the most devastating and lethal primary brain cancer [1, 2]

  • These results indicated that ATP1A1 is overexpressed in high-grade GBM and is generally upregulated in Glioma stem cells (GSCs) when compared with differentiated GBM cells

  • To screen for specific molecules expressed in GSCs, we previously performed a proteomics assay comparing GSCs and differentiated glioma cells, and we found that ATP1A1 is overexpressed in GSCs [7]

Read more

Summary

Introduction

Glioblastoma (GBM) is the most devastating and lethal primary brain cancer [1, 2]. Despite advances in aggressive surgery, radio-, and chemotherapy, GBM therapies are still limited and only palliative [3].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call